Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tocilizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tocilizumab overview

Tocilizumab (Actemra / Roactemra) is a humanized monoclonal antibody, acts as immunosupressant preparation. It is formulated as injectable solution and solution concentrate for intravenous, intravenous drip or subcutaneous route of administration. Actemra is indicated for the treatment of rheumatoid arthritis in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease modifying anti-rheumatic drugs via intravenous and subcutaneous route. Tocilizumab intravenous route is indicated for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis in patients of 2 years age and older. Roactemra, in combination with methotrexate (MTX), is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. It is also indicated to treat adults with temporal arteritis, takayasu arteritis, and vasculitis, for the treatment of cytokine release syndrome induced by tumor-specific T cell infusion therapy. Actemra (tocilizumab) is used as emergency treatment for coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is indicated for the treatment of pneumonia caused by SARS-CoV-2

The drug candidate is under development for the treatment of follicular lymphoma, metastatic hepatocellular carcinoma, non-small cell lung cancer, systemic sclerosis large-vessel vasculitis, giant cell arteritis, polymyalgia rheumatica, Behcet’s Uveitis, granulomatosis with polyangiitis, Schnitzler syndrome, pain, familial mediterranean fever, multiple myeloma (kahler disease) and diffuse large b-cell lymphoma. It is also under development for COVID-19 pneumonia and in hospitalized adult patients with severe COVID-19, sepsis and septic shock.

It was also under development for the treatment of idiopathic retroperitoneal fibrosis, pulmonary arterial hypertension, Grave's orbitopathy or thyroid eye disease, ankylosing spondylitis, giant lymph node hyperplasia and metastatic pancreatic cancer, polymyositis, dermatomyositis, amyotrophic lateral sclerosis and B-Cell Chronic Lymphocytic Leukemia.

Chugai Pharmaceutical overview

Chugai Pharmaceutical (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd, is focused on the research, development, commercialization, manufacturing, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. The company is operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

For a complete picture of Tocilizumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.